Incannex

Amended Loyalty Options Timetable

Highlights:

- Amended timetable below.

Melbourne, Australia, March 21, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs.
A revised timetable for the issue of Loyalty Options is detailed below.

Revised timetable for the Issue of Bonus Options and Additional Options

Announcement of Loyalty Option Offer	Friday, 18 March 2022
Lodgement of Appendix 3B with ASX	Monday, 21 March 2022
Record Date for Loyalty Option	Friday, 25 March 2022 (7.00pm Melbourne time)
Lodgement of Prospectus with ASIC	Friday, 25 March 2022
Lodgement of Prospectus and Appendix 3B with ASX	Friday, 25 March 2022
Issue of Loyalty Options and despatch of holding statements	Thursday, 31 March 2022
Loyalty Option Offer Closing Date	Thursday, 31 March 2022
Loyalty Option expiry date	Friday, 22 April 2022
Issue of Shares on the exercise of Loyalty Options and despatch of holding statements	Friday, 29 April 2022
Issue of Piggyback Options and despatch of new holding statements	Monday, 9 May 2022
Piggyback Options exercise expiry date	Friday, 28 April 2023

As the dates set out above are indicative only, the Company reserves the right to amend them subject to the requirements of the Corporations Act and the ASX Listing Rules. The Prospectus will be available for download from the ASX platform under Announcements or the Company's website www.incannex.com.au, as from the date of lodgement of the Prospectus with ASIC. A paper copy may be obtained from that time free of charge, by contacting Mr Madhukar Bhalla, Incannex's Company Secretary by email at madhu@incannex.com.au.

Eligible Shareholders are not obliged to take any action in relation to the issue of the Bonus Options.

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

This announcement has been approved for release to ASX by the Incannex board of directors.

ENDS

About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease. U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication represents major global markets and currently have no, or limited, existing registered pharmacotherapy (drug) treatments available to the public. IHL has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners.
Website: www.incannex.com.au
Investors: investors@incannex.com.au

Forward-looking statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.

Contact Information

Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au

US IR Contact
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com